Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Cardiff Oncology (CRDF) reported a Q4 loss of $0.21 per share, which was better than the Zacks Consensus Estimate of a $0.25 loss. This matches the loss per share from the previous year.
February 28, 2025 | 12:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cardiff Oncology reported a Q4 loss of $0.21 per share, better than the expected $0.25 loss, matching last year's performance.
The better-than-expected earnings report is likely to have a positive short-term impact on CRDF's stock price. Beating the consensus estimate often boosts investor confidence, potentially leading to a stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100